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INTRODUCTION
Despite its initial characterization
more than three centuries ago, little is
known about the molecular mechanisms
that give rise to classic Hodgkin’s lym-
phoma (cHL)† [1]. cHL is characterized by
the appearance of giant cells known as
Hodgkin and Reed-Sternberg (HRS) cells,
which serve as an important diagnostic
marker of the disease [1].§ Although HRS
cells had long been suspected to be the
pathogenic cells of cHL, only within the
last few years has this been proven to be
the case.
In 1999, Cossman et al. demonstrated
that HRS cells are derived from germinal
center B lymphocytes [1]. Germinal cen-
ters are specialized structures in secondary
lymphoid tissue that arise from the clonal
expansion of antigen-specific B cells dur-
ing an immune response. During germinal
center expansion, B cell immunoglobulin
genes hypermutate in order to increase
antibody affinity. Normally, the B cells
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Classic Hodgkin’s lymphoma is characterized by the appearance of giant abnormal cells
called Hodgkin and Reed-Sternberg (HRS) cells. HRS cells arise from germinal center B
lymphocytes and in about 50 percent of patients are infected with Epstein-Barr virus. In
addition, HRS cells show constitutive NF-ʺB activation and are resistant to apoptosis. This
paper reviews several recent studies that for the first time implicate specific molecules in
the pathogenesis of classic Hodgkin’s lymphoma. Targeting these molecules could lead to
the development of novel therapies for this disease.with mutated immunoglobulin genes that
give rise to low-affinity, unfavorable B
cell receptors (BCRs) are eliminated,
while those that give rise to high-affinity,
favorable BCRs survive. Somehow, HRS
cells acquire an ability to survive despite
having deleterious mutations.
In addition to evading cell death, HRS
cells exhibit other characteristic features.
Similar to many cancers, HRS cells show
constitutive activation of the transcription
factor nuclear factor kappa B (NF-ʺB),
which promotes cell growth. Moreover, a
substantial proportion of HRS cells carry
Epstein-Barr virus (EBV), a virus that
latently infects more than 95 percent of all
adults [2]. EBV infects and activates naive
B cells, causing them to proliferate.
Normally, this proliferation is short-lived
and drives the B cells into the B-cell mem-
ory pool, where they are harmlessly main-
tained. Given that EBV genes can promote
cell division, one hypothesis is that EBV
deregulation might cause aberrant B-cell
proliferation and lead to cHL [2].
However, in light of the large number of
people that carry EBV but never develop
cHL, the significance of this infection
remains uncertain. In the past few years, a
significant body of research has been pub-
lished that sheds light on the more detailed
molecular mechanisms that might con-
tribute to cHL. This review highlights
some of the current advances in the field
and discusses the therapeutic implications
of this progress as it relates to the develop-
ment of new therapies.
EPSTEIN-BARR VIRUS INFECTION
Nearly half of Hodgkin’s patients have
EBVDNAintheirtumorcells[3].However,
the role EBV infection might play in onco-
genesis is only just beginning to be under-
stood. EBV-infected HRS cells express very
few viral genes.Anotable exception is latent
membrane protein 2A (LMP2A), whose
gene product localizes to small glycolipid-
enriched microdomains in the plasma mem-
brane of these cells [4]. Previous work has
indicated that LMP2A might mimic an acti-
vated BCR and enable BCR-negative cells
that should be eliminated to inappropriately
exit the bone marrow and colonize peripher-
al lymphoid organs [5].
Arecent study by Portis et al. explored
the transcriptional profile of B cells
expressing the LMP2A transgene [4].
Using DNA microarray analysis, the
authors compared gene transcription in
bone marrow and splenic B cells from
LMP2Atransgenic mice, LMP2A-express-
ing human B-cell lines, and LMP2A-posi-
tive EBV-infected lymphoblastoid cell
lines. Overall, they found similar transcrip-
tional changes in the various cell types,
suggesting that LMP2A targets specific
cellular pathways. Interestingly, this tran-
scriptional profile showed many alterations
in gene expression similar to that found in
the HRS cells of Hodgkin’s lymphoma
patients. For example, many of the same B
cell-specific transcription factors and sig-
naling molecules were downregulated,
which might provide a mechanism for
these cells to avoid immune recognition
and apoptosis induction. In addition, vari-
ous cell-cycle, anti-apoptotic, and anti-
immunity genes were overexpressed,
which favors cell growth.
Such overexpression is a common fea-
ture of HRS cells in general, including those
cells that are EBV-negative. It is possible
that EBV-negative HRS cells contain other
elements that functionally replicate the
effects of LMP2A or initially were infected
withEBVbutlostviralgeneexpressiondur-
ing later stages of malignancy [4].
CONSTITUTIVE NF-Κ ΚB ACTIVATION
NF-ʺB is a transcription factor that reg-
ulates  the  expression  of  many  genes
involved in cell proliferation, inflammatory
response, and apoptosis. Constitutive NF-ʺB
activity is a hallmark of HRS cells, which
may help protect these cells from apoptosis
and enable them to grow in the absence of
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dimer of different subunits, including p50,
p65/RelA,  p52,  c-Rel  or  RelB.  Normally,
dimeric NF-ʺB is sequestered in the cyto-
plasm  by  binding  to  members  of  the
inhibitor  of  kappa  B  (IʺB)  family,  which
include IʺBα, IʺBβ, and IʺBʵ.  Upon treat-
ment of cells with certain stimuli, such as the
cytokine tumor necrosis factor (TNF) alpha,
one or more of the IʺB proteins is phospho-
rylated  by  the  IʺB  kinase  complex.  This
phosphorylation targets the IʺB proteins for
polyubiquitination and subsequent degrada-
tion by the 26S proteasome, releasing NF-
ʺB  and  enabling  it  to  translocate  to  the
nucleus, where it binds DNA and activates
transcription (for a detailed review of NF-ʺB
regulation, see [6]).
Recent  investigations  have  revealed
several mechanisms that appear to lead to
constitutive NF-ʺB activation and expres-
sion of NF-ʺB target genes in HRS cells
[7-9]. Previously, it was shown that muta-
tions in the IʺBα gene could lead to a non-
functional inhibitor that was unable to effi-
ciently sequester NF-ʺB in the cytoplasm
[10]. Now, Emmerich et al. have extended
their earlier work on IʺBα by analyzing
IʺBʵ for mutations in patients with cHL as
well as in cHL-derived cell lines [7]. PCR
and sequence analysis of 228 single HRS
cells from the lymph node sections of six
patients revealed that one of the patients
had  a  point  mutation  at  position  +5  of
intron 1 in the IʺBʵ gene, which led to a
splicing  deficiency.  Notably,  this  patient
did not have a mutation in IʺBα. 
The detected splicing deficiency led to
a frame shift followed by a pre-terminal
stop codon in exon 3, resulting in a trun-
cated IʺBʵ protein that was unable to inter-
act with NF-ʺB. In addition, the investiga-
tors analyzed the expression of IʺBʵ pro-
tein in six cHL-derived cell lines. Western
blot analysis revealed loss of IʺBʵ expres-
sion in one of these lines compared to the
other cHL-derived and control cell lines.
Together, these data suggest that defects in
the  various  NF-ʺB  inhibitory  molecules
may  be  more  frequently  involved  in  the
constitutive activation of NF-ʺB in HRS
cells than previously thought.
In  addition  to  mutations  in  the  IʺB
genes, genomic changes in the loci of the
NF-ʺB subunits have been implicated in
the pathogenesis of cHL. Structural aber-
rations of the short arm of chromosome 2,
most often resulting in gains of 2p13~16,
have been described as highly recurrent in
HRS  cells  [11].  This  gain  is  correlated
with  aberrant  fluorescence  in  situ
hybridization signal patterns of the NF-ʺB
subunit REL locus. 
Recently, Barth et al. investigated the
role of c-Rel in cHL [8]. Performing inter-
phase cytogenetics on 26 biopsies from 25
cHL patients, they found that 12 demon-
strated gains of chromosomal material of
2p13~16, which contains the REL locus.
Furthermore, immunohistochemical analy  -
sis of the c-Rel protein revealed that all 12
of these biopsies displayed nuclear staining
for c-Rel compared to control tissue, which
displayed predominant cytoplasmic stain-
ing. Moreover, many of the samples with-
out  gains  of  2p  also  displayed  nuclear
staining  of  c-Rel,  although  to  a  lesser
extent than the samples with gains of 2p. 
Given  that  NF-ʺB  is  active  in  the
nucleus, it is possible that enhanced nuclear
staining of c-Rel is indicative of enhanced
NF-ʺB activity. In all, this study demon-
strates a close correlation between chromo-
somal aberrations in 2p13~16 and nuclear
accumulation  of  c-Rel  and  suggests  that
genomic changes in the REL locus might be
a genetic mechanism that leads to constitu-
tive NF-ʺB activity in HRS cells. 
Another hallmark of HRS cells is the
overexpression of CD30, a member of the
TNF  receptor  superfamily  involved  in
cytokine  signaling.  Overexpression  of
CD30 results in ligand-independent con-
stitutive  signaling  that  activates  NF-ʺB,
however, the mechanism leading to CD30
overexpression in these cells is unclear. 
Watanabe  et  al.  have  recently  pub-
lished  a  study  reporting  that  aberrant
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dysregulation  of  the  CD30  promoter
region [9]. The CD30 promoter region is
comprised of three domains: a core pro-
moter  with  polymerase  binding  sites,  a
downstream  promoter  element  essential
for  start-site  selection,  and  an  upstream
microsatellite sequence (MS) that repress-
es core promoter activity. In their study,
Watanabe  et  al.  conducted  a  sequence
analysis of the CD30 MS region and found
a novel AP-1 binding site. AP-1, like NF-
ʺB, is a dimeric transcription factor com-
prised of a variety of different subunits, in
this case from the Jun and Fos families.
Using a gel-shift assay, the authors identi-
fied JunB as the nuclear factor that binds
this  AP-1  site.  Furthermore,  a  reporter
assay indicated that this binding blocks the
normal  suppression  of  the  CD30  MS
region and corresponds to an increase in
CD30 promoter activity. Finally, the inves-
tigators demonstrated that both HRS cell
lines and HRS cells from the lymph nodes
of  cHL  patients  constitutively  expressed
JunB. Therefore, they suggest that in HRS
cells,  elevated  JunB  levels  may  lead  to
inappropriate binding of the AP-1 site in
the CD30 MS region, resulting in a loss of
normal  CD30  promoter  suppression  and
consequent CD30 overexpression.  
RESISTANCE TO APOPTOSIS
Apoptosis, or programmed cell death,
is  an  important  regulatory  mechanism
whereby  unwanted  cells  are  eliminated.
This process is mediated by two distinct
signaling pathways, one that involves the
triggering of death domain-containing cell
surface  receptors  and  the  other  that
involves the release of proapoptotic fac-
tors from the mitochondria. One receptor
that mediates the former apoptotic path-
way  is  the  TNF  receptor  superfamily
member  CD95/Fas.  Normally,  activation
of  Fas  leads  to  the  recruitment  of  the
death-inducing signaling complex (DISC)
consisting  of  Fas,  the  adaptor  molecule
Fas-associated death domain (FADD), and
the  cysteine  protease  caspase-8.
Oligomerization of procaspase-8 results in
its autoproteolytic cleavage, which leads
to its activation and the onset of a cascade
of effector caspases that ultimately results
in cell death. Resistance to Fas-mediated
apoptosis is thought to play an important
role in the survival of the unfavorable ger-
minal center B cells that give rise to HRS
cells.  
One key player in Fas-mediated apop-
tosis is c-FLIP, the cellular homolog of the
viral  protein  v-FLIP  (FADD-like  IL-1β-
converting enzyme (FLICE)-like inhibito-
ry protein). c-FLIP can also be recruited to
the  DISC,  however,  its  recruitment
inhibits  the  recruitment  of  caspase-8.
Consequently, high levels of c-FLIP can
block Fas-mediated apoptosis by prevent-
ing the activation of the caspase cascade. 
A  significant  amount  of  work  has
been published in the last few years impli-
cating the overexpression of c-FLIP as a
major  mechanism  responsible  for  Fas-
resistance in cHL [12-15]. The first piece
of evidence came from Thomas et al. who
demonstrated  that  c-FLIP  was  overex-
pressed  in  both  Fas-resistant  HRS  cell
lines as well as in 18 of 19 cases of prima-
ry  Hodgkin’s  lymphoma,  as  revealed  by
immunohistochemical  analysis  [12].  A
subsequent  study  by  Maggio  et  al.
explored whether Fas-resistance is likely
due to this overexpression of c-FLIP or if
instead  is  due  to  mutations  in  Fas  [13].
They analyzed FAS gene mutations and c-
FLIP  expression  in  20  Hodgkin’s  lym-
phoma  tissue  samples  and  four  HRS-
derived  cell  lines  and  found  a  causative
FAS mutation in only one of the 20 prima-
ry cases and in one of the four cell lines.
Conversely,  they  detected  high  c-FLIP
expression  by  RT-PCR  or  immunohisto-
chemical analysis in all of the cell lines
and primary cases. They suggest that Fas
mutations are rare and c-FLIP overexpres-
sion is a more likely cause of Fas-resis-
tance in HRS cells.
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lished  providing  strong  evidence  that  c-
FLIP indeed mediates Fas-resistance and
protects  HRS  cells  from  cell  death  [14,
15]. Using small interfering RNA oligonu-
cleotides (siRNAs) specific for c-FLIP or
Fas ligand, Dutton et al. showed that the
downregulation  of  c-FLIP  in  two  cHL-
derived cell lines resulted in increased cell
death, whereas the concomitant downreg-
ulation of Fas ligand in both of these cell
lines prevented this cell death [14]. 
Mathas  et  al.  also  demonstrated  that
the specific downregulation of c-FLIP by
siRNA transfection in two cHL-derived cell
lines sensitized these cells to Fas-mediated
apoptosis [15]. In addition, Mathas’ group
performed  immunohistochemical  analysis
of  the  DISC  members  in  59  cases  of
Hodgkin’s lymphoma and found that Fas
and  c-FLIP  were  overexpressed  in  55  of
these cases, and FADD was overexpressed
in several compared to surrounding normal
cells. These data indicate that the Fas-medi-
ated  apoptotic  pathway  is  upregulated  in
HRS cells and that c-FLIP is a key regula-
tor of resistance in these cells.
In addition to death domain-mediated
apoptotic  signaling,  apoptosis  can  be  sig-
naled through the mitochondria. In this case,
proapoptotic factors such as cytochrome c
and second mitochondria-derived activator
of caspases (Smac) are released from the
mitochondria and initiate a caspase cascade
via caspase-9. More specifically, cytosolic
cytochrome c, procaspase-9, and apoptosis
protease-activating factor-1 (Apaf-1) form a
complex  called  the  apoptosome,  which
induces  the  activation  of  caspase-9  by
dimerization. Similar to caspase-8, activated
caspase-9 initiates a cascade of effector cas-
pases, which ultimately leads to cell death. 
A  family  of  proteins,  known  as  the
inhibitors of apoptosis, modulates the activ-
ity of the caspases and prevents unwanted
cell  death.  Recently,  Kashkar  et  al.  have
implicated  one  of  these  molecules,  X-
linked inhibitor of apoptosis (XIAP), in the
pathogenesis of cHL [16]. XIAP can bind
the effector caspase, caspase-3, and block
its activation, thereby inhibiting apoptosis.
In their study, Kashkar et al. showed via
coimmunoprecipitation that XIAP, Apaf-1,
and caspase-3 were bound in cHL-derived
B cells and that stimulation by exogenous
cytochrome c could not block this interac-
tion. Furthermore, they demonstrated that
caspase-3 activity could be restored in these
cells in the presence of the XIAP inhibitor
Smac or if the cells were immunodepleted
of XIAP. Finally, the investigators showed
that  both  cHL-derived  B  cells  and  HRS
cells from primary cases of Hodgkin’s lym-
phoma  constitutively  and  abundantly
expressed XIAP. Together, these data sug-
gest that XIAP overexpression may confer
apoptosis resistance to HRS cells. 
Beyond direct defects in the apoptotic
pathways,  apoptosis  resistance  can  be
incurred in cells that acquire changes that
allow  them  to  bypass  the  cellular  check-
points  that  would  normally  stimulate  the
apoptotic pathways. One class of genes that
regulate such checkpoints is the tumor sup-
pressor  genes.  Loss  of  function  of  both
copies of a tumor suppressor gene is charac-
teristic of many cancers and enables inap-
propriate growth. Epigenetic inactivation of
one such tumor suppressor, RASSF1A, has
been observed in many solid tumors. Murray
et al. have recently published data that this
might also be the case in cHL [17]. They
found that of six cHL-derived cell lines, four
had hypermethylated RASSF1A promoters
and did not express the gene. Demethylation
of the promoter restored RASSF1A expres-
sion in these cells. In addition, hypermethy-
lation of RASSF1A was detected in 34 of 52
(65  percent)  primary  cases  of  Hodgkin’s
lymphoma.  Consequently,  inactivation  of
RASSF1A may be yet another mechanism
by which HRS progenitors escape apoptosis
and become pathogenic. 
CONCLUSIONS
One hallmark of cHL is the presence of
HRS  cells.  Until  recently,  very  little  was
Felberbaum: Mechanisms of Hodgkin’s lymphoma 205known about the molecular mechanisms of
these  pathogenic  germinal  center  B  cells,
except that they show constitutive NF-ʺB
activity, are resistant to apoptosis, and some-
times carry Epstein-Barr virus. In the past
few years, significant advances have been
made  further  defining  the  mechanisms  at
play (Table 1). In those patients infected with
EBV,  the  expression  of  viral  LMP2A  has
been shown to give rise to a transcriptional
profile that enables cells to inappropriately
survive and proliferate. In other cases, muta-
tions in IʺB or REL, or overexpression of
JunB have been shown to lead to constitutive
NF-ʺB activity. In addition, the overexpres-
sion of c-FLIP or XIAP, or the inactivation
of the RASSF1A tumor suppressor gene has
been shown to contribute to the resistance of
HRS cells to apoptosis. Taken together, these
mutations begin to paint a clearer picture of
what  goes  wrong  in  cHL  and  represent
potential targets for new therapies.
According  to  the  United  States
National  Cancer  Institute,  an  estimated
7,300 new patients will be diagnosed with
Hodgkin’s lymphoma this year. Notably,
65 percent of Hodgkin’s patients are under
the age of 40 years. Older treatments for
the  disease  were  often  associated  with
serious  complications  from  therapy,
including sterility and high incidence rates
of  secondary  cancers.  Given  the  young
population  of  patients,  these  toxicities
were not acceptable. 
Today, the standards of care, such as
the  chemotherapy  combination  ABVD
(Adriamycin,  Bleomycin,  Vinblastine,
Dacarbazine) followed by the selective use
of  low-dose  radiation,  have  dramatically
reduced  treatment  side  effects  and
improved cure rates. Over 90 percent of
patients  with  early-stage  disease  will  be
cured  by  this  or  a  similar  type  of  treat-
ment.  Moreover,  about  40  percent  of
patients suffering a relapse will be cured
by other treatment regimens, such as high-
dose  chemotherapy  and  autologous
peripheral  stem  cell  transplantation.
Despite this improvement, there is still a
need to develop new therapies.
By  defining  the  molecular  mecha-
nisms of cHL, new therapeutic targets are
identified  that  could  give  rise  to  a  new
generation of rationally designed therapies
that may be even more effective and less
toxic than current treatments. For instance,
in those patients infected with EBV, a drug
that  could  successfully  downregulate
LMP2A  could  also  potentially  alleviate
the  aberrant  transcriptional  profile  of
infected cells. LMP2A is an excellent drug
target since it is a viral protein and is not
expressed in normal cells. Consequently, a
therapy  designed  against  LMP2A  would
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Table 1. Summary of the molecular mechanisms of classic Hodgkin’s lymphoma
reviewed in this paper.
Molecular Mechanisms of Classic Hodgkin’s Lymphoma
Epstein-Barr Virus-positive cells:
Viral LMP2A expression leads to an aberrant transcriptional profile
Epstein-Barr Virus-positive or negative cells:
Constitutive NF-ʺB activity leads to inappropriate cell growth:
• Arises from mutations in IʺB
• Arises from mutations in REL 
• Arises from JunB overexpression leading to CD30 overexpression
Resistance to apoptosis prevents cell death:
• Arises from c-FLIP overexpression
• Arises from XIAP overexpression
• Arises from inactivation of the tumor suppressor gene RASSF1Abe  very  specific  for  infected  cells  and
potentially less toxic to patients. In addi-
tion,  the  studies  on  c-FLIP  indicate  that
HRS cells are already primed for apopto-
sis. Therefore, the selective downregula-
tion of c-FLIP could also serve as a novel
treatment that would specifically kill HRS
cells.  Recently,  the  use  of  proteasome
inhibitors has been found to be an effec-
tive treatment for some cancers. For exam-
ple, the drug bortezomib, which is a pro-
teasome  inhibitor  now  approved  for  the
treatment of multiple myeloma, has been
shown to not only inhibit NF-ʺB but also
promote  cell  cycle  arrest  and  apoptosis
[18]. Given the elevated activity of NF-ʺB
and  the  anti-apoptotic  character  of  HRS
cells, it would be interesting to determine
whether  a  similar  approach  would  also
prove  fruitful  for  cHL,  although  this
remains to be tested. It is important that
drug  designers  incorporate  these  and
future  findings  into  the  development  of
new  therapies  so  that  the  best  possible
treatments become available.
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